Mainboard · BSE and NSEListed

SYMBIOTEC PHARMALAB LIMITED IPO: dates, price band, lot size, objects of the issue

Get analyst updates on this IPO

Analyst updates come by email.

What changed since listing, from SEBI-registered research analysts.

By continuing you agree to the Terms and Privacy policy

Updated Mon 16 Nov 2026, 12:12 pm IST · Source: Basis of allotment dated Mon 31 Aug 2026

Bid dates
Mon 24 Aug 2026 to Thu 27 Aug 2026
Listing date
Tue 1 Sep 2026
Issue price
₹988 per share

Listed on BSE and NSE on Tue 1 Sep 2026.

Listing price ₹978.20

Opening price on BSE on the listing day (BSE daily price file for Tue 1 Sep 2026)

This page is now frozen. Facts stay as filed; the quote is on the exchange.

Key facts

Issue price
₹988 per share
groww.in, as of Mon 16 Nov 2026
Lot size
Not stated in the RHP
RHP dated Tue 18 Aug 2026
Lot amount at the upper band
Not stated in the RHP
RHP dated Tue 18 Aug 2026
Issue size at the upper band
₹1,757.00 crore
Fresh issue
₹150.00 crore
RHP dated Tue 18 Aug 2026, page 82
Offer for sale
₹1,607.00 crore
RHP dated Tue 18 Aug 2026, page 82
Bid dates
Mon 24 Aug 2026 to Thu 27 Aug 2026
RHP dated Tue 18 Aug 2026, page 2
Listing date
Tue 1 Sep 2026
BSE daily price file for Tue 1 Sep 2026
Anchor lock-in ends
Set after bidding
RHP dated Tue 18 Aug 2026
Risk factors
97
RHP dated Tue 18 Aug 2026, page 80

Timeline (IST)

  1. OpensMon 24 Aug 2026, 10:00 am IST confirmedRHP dated Tue 18 Aug 2026, page 2
  2. ClosesThu 27 Aug 2026 confirmedRHP dated Tue 18 Aug 2026, page 2
  3. UPI mandate cut-offNot stated in the RHP RHP dated Tue 18 Aug 2026
  4. AllotmentFri 28 Aug 2026 by T+3 schedule
  5. Refund and unblockMon 31 Aug 2026 by T+3 schedule
  6. Shares to dematMon 31 Aug 2026 by T+3 schedule
  7. ListingTue 1 Sep 2026 confirmedBSE daily price file for Tue 1 Sep 2026

Objects of the issue

ObjectAmount
Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company₹112.50 crore
General corporate purposesNot stated in the RHP
TotalNot stated in the RHP

The ₹1,607.00 crore offer for sale goes to the selling shareholders, not the company. RHP dated Tue 18 Aug 2026, page 138

Company and promoters

As described in the RHP

We are a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables.

RHP dated Tue 18 Aug 2026, page 218

Promoters

  • Satwani Holdings LLP
  • 3 individual promoters

RHP dated Tue 18 Aug 2026, page 301

Shareholding

HoldingBefore the issueAfter the issue
Promoters and promoter group36.41%Not stated in the RHP
Public63.59%Not stated in the RHP

RHP dated Tue 18 Aug 2026, page 130

Financials (restated)

ItemMarch 31, 2026March 31, 2025March 31, 2024
Revenue from operations₹869.15 crore₹751.55 crore₹716.25 crore
Profit after tax₹109.90 crore₹96.79 crore₹100.06 crore
Net worth₹1,149.73 crore₹814.89 crore₹715.05 crore
Total borrowingsNot stated in the RHPNot stated in the RHPNot stated in the RHP

RHP dated Tue 18 Aug 2026, page 86

Who is selling in the offer for sale

Selling shareholderTypeShares offeredAmount at the upper band
Satwani Holdings LLPCompanyNot announcedNot stated in the RHP
Rosewood InvestmentsOtherNot announcedNot stated in the RHP
Individual shareholderIndividualNot announcedNot stated in the RHP
Total offer for sale₹1,607.00 crore

RHP dated Tue 18 Aug 2026, page 82

Peer comparison (as in the RHP)

Name of the companyFace value (₹ per equity share)Closing price on August 17, 2026 (₹)Revenue from operations for Fiscal 2026 (in ₹ million)EPS (₹) for Fiscal 2026 BasicEPS (₹) for Fiscal 2026 DilutedNAV (₹ per equity share) for Fiscal 2026P/E ratio as on August 17, 2026RoNW for Fiscal 2026 (%)
Symbiotec Pharmalab Limited2N.A.8,691.4919.1019.00184.69NA9.48%
Concord Biotech Limited11,513.4010,549.0024.7824.78NA61.0714.00%
Divi's Laboratories Limited28,495.00105,600.0096.7596.75631.0087.8016.50%
Cohance Lifesciences Limited1444.7022,685.504.694.68NA95.027.00%
Laurus Labs Limited21,799.0068,129.0016.4716.45NA109.3616.80%

Reproduced from the RHP dated Tue 18 Aug 2026, page 150; InsightPier adds no figures

Risk factors

97 total
  1. Almost all revenue comes from selling APIs, and the top five APIs make up most of it (RHP page 28)
  2. Plants face regulator and customer inspections; quality failures could bring regulatory action (RHP page 30)
  3. Most revenue comes from exports, which carry overseas risks (RHP page 31)
  4. US tariffs or anti-outsourcing laws could hurt results (RHP page 32)
  5. A large share of revenue comes from a few key customers (RHP page 33)

All 97 risk factors, RHP pages 28 to 81

Offer document

Allotment and bids

Registrar to the issue: MUFG Intime India Private Limited.

Allotment status was expected on the registrar's site from Fri 28 Aug 2026 and is not yet confirmed. Pick "SYMBIOTEC PHARMALAB LIMITED" from the issue list there.

Subscription (final)

CategoryShares offeredShares bid forTimes subscribed
Eligible Employees33,4075,37,09016.08×
Retail Individual Investors62,13,5638,54,50,11013.75×
Qualified Institutional Bidders (excluding Anchor Investors)35,50,60764,21,33,275180.85×
Non Institutional Investors -More than 0.2 Million Upto 1 Million8,87,6525,19,87,18058.57×
Non Institutional Investors -Above 1 Million17,75,30415,58,14,51087.77×
Anchor Investors53,25,90954,96,1651.03×
Total1,24,60,53393,59,22,16575.11×

Total: Excluding anchor investors

Basis of allotment dated Mon 31 Aug 2026, page 2

Research

Research reports on IPOs from SEBI-registered research analysts, published on InsightPier.

Research reports on IPOs from SEBI-registered research analysts